FY2025 EPS Estimate for Oncolytics Biotech Raised by Analyst

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at Leede Financial upped their FY2025 EPS estimates for shares of Oncolytics Biotech in a research report issued on Monday, March 10th. Leede Financial analyst D. Loe now anticipates that the company will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.41). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Shares of TSE ONC opened at C$0.91 on Thursday. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a market cap of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35. The firm’s fifty day moving average is C$1.10 and its two-hundred day moving average is C$1.30. Oncolytics Biotech has a 52-week low of C$0.86 and a 52-week high of C$2.08.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.